On Sept. 11, 2015, AstraZeneca announced it had purchased the former Synergen LakeCentre biologics bulk manufacturing facility in Boulder, Colorado from Amgen for $14.6 million.

AstraZeneca planned to start staffing the facility immediately to support refurbishment and infrastructure improvements. Once complete, the site was expected to be operational and licensed for commercial production by late 2017, providing for additional capacity within the company’s biologics operations.